CYTUNEPHARMA
Cytune is a private company developing a broad portfolio of novel immunotherapeutic agents to treat primarily cancer. Cytune’s hedge relies on a proprietary scientific breakthrough in immunology: effective form of a major human immunocytokine: trans-presentation mechanism of a critical immune factor: IL-15 Cytune’s proprietary most advanced proprietary compound, CYP 0150, is a human interleukin-15 uniquely linked to its effector. Cytune is further developing conjugated monoclonal antibodies linked to CYP 0150. Cytune was founded in 2007 and is managed by Dr. David Bechard, a successful serial biotech entrepreneur and Dr. Yannick Jacques, Director of Public Research at the Inserm (National Institute for Health and Medical Research)
CYTUNEPHARMA
Social Links:
Industry:
Biotechnology Pharmaceutical Therapeutics
Founded:
2007-01-01
Address:
Nantes, Pays De La Loire, France
Country:
France
Website Url:
http://www.cytunepharma.com
Total Employee:
1+
Status:
Active
Contact:
+33 2 40 08 47 23
Total Funding:
6.66 M USD
Technology used in webpage:
SPF Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS
Similar Organizations
DataHow
DataHow offers digital solutions and consulting for process screening, monitoring, optimization, control and scale-up.
Exponential Biotherapies
Exponential Biotherapies develops therapeutics to attenuate overreactions of the immune system.
Current Employees Featured
Founder
Investors List
PPF Group
PPF Group investment in Venture Round - CytunePharma
PPF Group
PPF Group investment in Venture Round - CytunePharma
ABAB (Atlantic Business Angels Booster)
ABAB (Atlantic Business Angels Booster) investment in Venture Round - CytunePharma
Official Site Inspections
http://www.cytunepharma.com
- Host name: unassigned-ip.savana.cz
- IP address: 185.183.11.92
- Location: Czechia
- Latitude: 50.0848
- Longitude: 14.4112
- Timezone: Europe/Prague
